FDA — authorised 19 March 2014
- Application: NDA204684
- Marketing authorisation holder: KNIGHT THERAPS
- Local brand name: IMPAVIDO
- Indication: CAPSULE — ORAL
- Status: approved
🇺🇸 liposomal amphotericin B + miltefosine in United States
FDA authorised liposomal amphotericin B + miltefosine on 19 March 2014
Marketing authorisation
Other Infectious Diseases approved in United States
Frequently asked questions
Is liposomal amphotericin B + miltefosine approved in United States?
Yes. FDA authorised it on 19 March 2014.
Who is the marketing authorisation holder for liposomal amphotericin B + miltefosine in United States?
KNIGHT THERAPS holds the US marketing authorisation.